314 related articles for article (PubMed ID: 17768685)
21. Effect of Hypoxia on DDR1 Expression in Pituitary Adenomas.
Li S; Zhang Z; Xue J; Guo X; Liang S; Liu A
Med Sci Monit; 2015 Aug; 21():2433-8. PubMed ID: 26286316
[TBL] [Abstract][Full Text] [Related]
22. The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma.
Altaş M; Bayrak OF; Ayan E; Bolukbasi F; Silav G; Coskun KK; Culha M; Sahin F; Sevli S; Elmaci I
Acta Neurochir (Wien); 2010 Sep; 152(9):1611-7; discussion 1617. PubMed ID: 20437278
[TBL] [Abstract][Full Text] [Related]
23. The Relationship Between Phospho-p38, Matrix Metalloproteinase 9, and Major Histocompatibility Complex Class I Chain-Related Molecule A Expression in Pituitary Adenomas Demonstrates a New Mechanism of Pituitary Adenoma Immune Escape.
Han X; Geng X; Li Z; Chen Z; Liu Y; Liu P; Wang Q; Li C; Ai D; Li Z
World Neurosurg; 2019 Mar; 123():e116-e124. PubMed ID: 30458325
[TBL] [Abstract][Full Text] [Related]
24. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
25. Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
Wu S; Gu Y; Huang Y; Wong TC; Ding H; Liu T; Zhang Y; Zhang X
Biochem Genet; 2017 Jun; 55(3):253-267. PubMed ID: 28315020
[TBL] [Abstract][Full Text] [Related]
26. CD147 expression in pituitary adenomas and its significance for clinical outcome.
Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of pituitary adenoma cell invasion and adhesion is mediated by discoidin domain receptor-1.
Yoshida D; Teramoto A
J Neurooncol; 2007 Mar; 82(1):29-40. PubMed ID: 17001518
[TBL] [Abstract][Full Text] [Related]
28. Wnt4 is overexpressed in human pituitary adenomas and is associated with tumor invasion.
Li W; Zhang Y; Zhang M; Huang G; Zhang Q
J Clin Neurosci; 2014 Jan; 21(1):137-41. PubMed ID: 24200887
[TBL] [Abstract][Full Text] [Related]
29. [Expression of peroxisome proliferator-activated receptor-gamma in human pituitary adenomas and its correlation to tumor invasiveness].
Huang CX; Hou YH; Zhao JN; Wang YT; Li JJ; Wen L
Ai Zheng; 2008 Jun; 27(6):590-4. PubMed ID: 18570731
[TBL] [Abstract][Full Text] [Related]
30. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space.
Pan LX; Chen ZP; Liu YS; Zhao JH
J Neurooncol; 2005 Aug; 74(1):71-6. PubMed ID: 16078111
[TBL] [Abstract][Full Text] [Related]
31. T3 receptors in human pituitary tumors.
Machiavelli GA; Pauni M; Heredia Sereno GM; Szijan I; Basso A; Burdman JA
Neurol Res; 2009 Nov; 31(9):928-30. PubMed ID: 19138463
[TBL] [Abstract][Full Text] [Related]
32. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker.
Bates AS; Farrell WE; Bicknell EJ; McNicol AM; Talbot AJ; Broome JC; Perrett CW; Thakker RV; Clayton RN
J Clin Endocrinol Metab; 1997 Mar; 82(3):818-24. PubMed ID: 9062489
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
34. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
35. Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness.
Takino H; Herman V; Weiss M; Melmed S
J Clin Endocrinol Metab; 1995 May; 80(5):1733-8. PubMed ID: 7745027
[TBL] [Abstract][Full Text] [Related]
36. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour.
McCabe CJ; Khaira JS; Boelaert K; Heaney AP; Tannahill LA; Hussain S; Mitchell R; Olliff J; Sheppard MC; Franklyn JA; Gittoes NJ
Clin Endocrinol (Oxf); 2003 Feb; 58(2):141-50. PubMed ID: 12580928
[TBL] [Abstract][Full Text] [Related]
37. [Preliminary study of p16 gene expression in pituitary adenomas].
Yu WH; Hui GZ; Wang Q; Wu SR
Ai Zheng; 2003 Feb; 22(2):198-201. PubMed ID: 12600300
[TBL] [Abstract][Full Text] [Related]
38. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas.
Feng J; Yu SY; Li CZ; Li ZY; Zhang YZ
Mol Cell Endocrinol; 2016 Nov; 436():195-203. PubMed ID: 27465831
[TBL] [Abstract][Full Text] [Related]
39. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Elnemr A; Yonemura Y; Bandou E; Kinoshita K; Kawamura T; Takahashi S; Tochiori S; Endou Y; Sasaki T
Gastric Cancer; 2003; 6(1):30-8. PubMed ID: 12673424
[TBL] [Abstract][Full Text] [Related]
40. Expression and clinical significance of doublecortin (DCX) in pituitary adenoma.
Liu X; Ma L; Wang Z; Ye J; Liu X; Jiang G; Wang H
Bull Cancer; 2019 Dec; 106(12):1080-1085. PubMed ID: 31376915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
